New pill takes on rare salivary gland and colon cancers

NCT ID NCT06462183

Recruiting now Disease control Sponsor: Rgenta Therapeutics Inc Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing an experimental oral drug called RGT-61159 in about 105 people with two types of cancer that have come back or stopped responding to treatment: adenoid cystic carcinoma (a rare salivary gland cancer) and colorectal cancer. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must have measurable disease that has progressed after prior therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RGT-61159 (an oral MYB inhibitor)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced adenoid cystic carcinoma or colorectal cancer that has stopped responding to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 105 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenoid cystic carcinoma colorectal cancer colorectal carcinoma colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOID CYSTIC CARCINOMA COLORECTAL CANCER

Contacts and locations

Locations

Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
RECRUITING

New York, New York, 10016, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Next Oncology VA
RECRUITING

Fairfax, Virginia, 22031, United States
Ottawa Hospital Cancer Centre
RECRUITING

Ottawa, Ontario, K1H 8L6, Canada
Princess Margaret Cancer Center
RECRUITING

Toronto, Ontario, M5G 2M9, Canada
University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.